Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials
Axel Dignaß(Goethe University Frankfurt), Walter Reinisch(Medical University of Vienna), Heidrun Heinemann(Dr Falk Pharma (Germany)), Ralph Müeller(Dr Falk Pharma (Germany)), Tanja Kuehbacher, Е. Б. Авалуева(North-Western State Medical University named after I.I. Mechnikov), Klaus Fellermann(Apple (Israel)), Jost Langhorst(ThyssenKrupp (Germany)), Gottfried Novacek(Medical University of Vienna), M. Horyński(Sopot University of Applied Science), Wolfgang Stremmel(University Hospital Heidelberg), Peter Hasselblatt(University Medical Center Freiburg), Roland Greinwald(Dr Falk Pharma (Germany)), Andrey Dorofeyev(Research Institute of Ukrainian Studies), Oleksandr Poyda(Bogomolets National Medical University), Peter Uebel(Ludwigshafen University of Business and Society), Oleksandr Oliinyk, Peter Armerding(Pathodiagnostik Berlin)
Cited by 4
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Survival and Causes of Death in Cirrhotic and in Noncirrhotic Patients with Primary Hemochromatosis
|New England Journal of Medicine|1985|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969